• 1
    Harris EN, Asherson RA, Gharavi AE, Morgan SH, Derue G, Hughes GR. Thrombocytopenia in SLE and related autoimmune disorders: association with anti-cardiolipin antibody. Br J Haematol 1985; 59: 22730.
  • 2
    Khamashta MA, Harris EN, Gharavi AE, Derue G, Gil A, Vazquez JJ, et al. Immune mediated mechanism for thrombosis: antiphospholipid antibody binding to platelet membranes. Ann Rheum Dis 1988; 47: 84954.
  • 3
    Out HJ, deGroot P, van Vliet M, de Gast G, Nieuwenhuis K, Derksen RH. Antibodies to platelets in patients with antiphospholipid antibodies. Blood 1991: 77: 26559.
  • 4
    Shatter Y, Tall Y, Greenberg A, Brenner B. Platelet activation in patients with antiphospholipid syndrome. Blood Coag Fibrinol 1998; 9: 6537.
  • 5
    Hasselaar P, Derksen RH, Blokzijl L, deGroot PG. Crossreactivity of antibodies directed against cardiolipin, DNA, endothelial cells and blood platelets. J Thromb Haemost 1990; 63: 16973.
  • 6
    Lellouche F, Martinuzzo M, Said P, Maclouf J, Carreras LO. Imbalance of thromboxane/prostacyclin biosynthesis in patients with lupus anticoagulant. Blood 1991; 78: 28949.
  • 7
    Campbell A, Pierangeli SS, Wellhausen S, Harris EN. Comparison of the effects of anticardiolipin antibodies from patients with the antiphospholipid syndrome and with syphilis on platelet activation and aggregation. J Thromb Haemost 1995; 73: 52934.
  • 8
    Espinola RG, Pierangeli SS, Gharavi AE, Harris EN. Hydroxychloroquine reverses platelet activation induced by human IgG antiphospholipid antibodies. J Thromb Haemost 2002; 87: 51822.
  • 9
    Ling YL, Wang CT. Activation of human platelets by the rabbit anticardiolipin antibodies. Blood 1992; 80: 313543.
  • 10
    Robbins DL, Leung S, Miller-Blair DJ, Ziboh V. Effect of anticardiolipin/β2 glycoprotein I complexes on production of thromboxane A2 by platelets from patients with the antiphospholipid syndrome. J Rheumatol 1998; 25: 516.
  • 11
    Buschbeck M, Ghomashchi F, Gelb MH, Watson SP, Borsch-Haubold AG. Stress stimuli increase calcium-induced arachidonic acid release through phosphorylation of cytosolic phospholipase A2. Biochemistry 1999; 344: 35966.
  • 12
    Borsch-Haubold AG, Ghomashchi F, Pasquet S, Goedert M, Cohen P, Gelb MH, et al. Phosphorylation of cytosolic phospholipase A2 in platelets is mediated by multiple stress-activated protein kinase pathways. Eur J Biochem 1999; 265: 195203.
  • 13
    Nadal-Wollbold F, Pawlowski M, Levy-Toledano S, Berrou E, Rosa JP, Brycjaert M. Platelet ERK2 activation by thrombin is dependent on calcium and conventional protein kinases C but not Raf-1 or B-Raf. FEBS Lett 2002; 531: 47582.
  • 14
    Levy-Toledano S, Gallet C, Nadal F, Bryckaert M, Maclouf J, Rosa J-P. Phosphorylation and dephosphorylation mechanisms in platelet function: a tightly regulated balance. J Thromb Haemost 1997; 78: 22633.
  • 15
    Levy-Toledano S. Platelet signal transduction pathways: could we organize them into a “hierarchy”? Haemostasis 1999: 29: 415.
  • 16
    Wang L, Su CY, Chou KY, Wang CT. Enhancement of human platelet activation by the combination of low concentrations of collagen and rabbit anticardiolipin antibodies. Br J Haematol 2002; 118: 115262.
  • 17
    Wilson WA, Gharavi AE, Koike T, Lockshin MD, Branch DW, Piette JC, et al. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. Arthritis Rheum 1999; 42; 130911.
  • 18
    Harris EN. Annotation: antiphospholipid antibodies. Br J Haematol 1990; 74: 19.
  • 19
    Palomo I, Pereira J, Alarcon M, Larrain AM, Pinochet C, Vasqez M, et al. Antiphospholipid antibodies in Chilean patients with systemic lupus erythematosus. J Lab Clin Med 2002; 14: 33641.
  • 20
    Exner T, Ricard KA, Kronenberg H. A sensitive test demonstrating lupus anticoagulant and its behavioral patterns. Br J Haematol 1985; 59: 22730.
  • 21
    Hackeng CM, Relou IA, Pladet MA, Gorter G, van Rijn HJ, Akkerman JW. Early platelet activation by low density lipoprotein via p38MAP kinase. J Thromb Haemost 1999; 82: 174956.
  • 22
    Davies SP, Reddy H, Caivano M, Cohen M. Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochemistry 2000: 351: 95105.
  • 23
    Pierangeli SS, Liu X, Barker JH, Anderson G, Harris EN. Induction of thrombosis in a mouse model by IgG, IgM and IgA immunoglobulins from patients with the antiphospholipid syndrome. J Thromb Haemost 1995; 74: 13617.
  • 24
    Espinola RG, Liu X, Colden-Stanfield M, Hall J, Harris EN, Pierangeli SS. E-selectin mediates pathogenic effects of antiphospholipid antibodies. J Thromb Haemost 2003; 1: 8438.
  • 25
    Jankowski M, Vreys L, Wittevrongel C, Boon D, Vermylen J, Hoylaerts MD, et al. Thrombogenicity of β2glycoprotein I dependent antiphospholipid antibodies in a photochemically induced thrombosis model in the hamster. Blood 2002; 101: 15762.
  • 26
    Martinuzzo ME, Maclouf J, Carreras LO, Levy-Toledano S. Antiphospholipid antibodies enhance thrombin-induced platelet activation and thromboxane formation. J Thromb Haemost 1993: 70: 66771.
  • 27
    Arvieux J, Rousell B, Pouzol P, Colomb MG. Platelet activating properties of murine monoclonal antibodies to β2glycoprotein I. J Thromb Haemost 1993; 70: 33641.
  • 28
    Opara R, Robbins DL, Ziboh VA. Cyclic-AMP agonists inhibit antiphospholipid/β2 gycoprotein I induced synthesis of human platelet thromboxane A2 in vitro. J Rheumatol 2003; 30: 559.
  • 29
    Gonzalez-Buritica H, Khamashta MA, Hughes GR. Is there a role for phospholipases in the anti-cardiolipin syndrome? Clin Exp Rheumatol 1988; 6: 3412.
  • 30
    Kramer R, Roberts M, Manetta EF, Hyslop JV, Jakubowski JA. Thrombin-induced phosphorylation and activation of Ca2+. J Biol Chem 1993; 268: 26796804.
  • 31
    Hefner Y, Borsch-Haubold AG, Murakami M, Wilde JI, Pasquet S, Schielts D, et al. Serine 727 phosphorylation and activation of cytosolic phospholipase A2 by MNK1-related protein kinases. J Biol Chem 2000; 275: 3754251.
  • 32
    Lin LL, Wartmann M, Lin AY, Knopf JL, Seth A, Davis RJ. cPLA2 is phophorylated and activated by MAP kinase. Cell 1993: 72: 26978.
  • 33
    Nemenoff RA, Winitz S, Qian NX, Van Putten V, Johnson GL, Heasley LE. Phosphorylation and activation of a high molecular weight form of phospholipase A2 by p42 microtubule-associated protein 2 kinase and protein kinase. J Biol Chem 1993; 268: 19604.
  • 34
    Borsch-Haubold AG, Bartoli F, Asselin J, Dudler T, Kramer RM, Apitz-Castro R, et al. Identification of the phosphorylation sites of cytosolic phospholipasse A2 in agonist-stimulated human platelets and HeLA cells. J Biol Chem 1998; 273: 444958.
  • 35
    Borsch-Haubold AG, Kramer RM, Watson SP. Cytosolic phospholipase A2 is phosphorylated in collagen- and thrombin-stimulated human platelets independent of protein kinase C and mitogen-activated protein kinase. J Biol Chem 1995; 270: 2588598.
  • 36
    Saklatvala J, Rawlinson L, Waller RJ, Sarsfield S, Lee JC, Morton LF, et al. Role for p38 mitogen-activated protein kinase in platelet aggregation caused by collagen or a thromboxane analog. J Biol Chem 1996; 271: 65869.
  • 37
    Borsch-Haubold AG, Kramer RM, Watson SP. Inhibition of mitogen-activated protein kinase kinase does not impair primary activation of human platelets. Biochemistry 1996; 318: 20712.
  • 38
    Kramer RM, Roberts EF, Um SL, Borsch-Haubold AG, Watson SP, Fisher MJ, et al. p38 mitogen-activated protein kinase phosphorylates cytosolic phospholipase A2 (cPLA2) in thrombin-stimulated platelets: evidence that proline-directed phosphorylation is not required for mobilization of arachidonic acid by cPLA2. J Biol Chem 1996; 271: 277239.
  • 39
    Borsch-Haubold AG, Pasquet S, Watson SP. Direct inhibition of cyclooxygenase-1 and -2 by the kinase inhibitors SB203580 and PD98059. J Biol Chem 1998; 273: 2876672.
  • 40
    Lutters BC, Derksen RH, Tekelnenburg WL, Lenting PJ, Arnout J, De Groot PG. Dimers of β2-glycoprotein I increase platelet deposition to collagen via interaction with phospholipids and the apolipoprotein E receptor 2. J Biol Chem 2003; 278: 338318.